Saponins, IL12 and BCG adjuvant in the FML-vaccine formulation against murine visceral leishmaniasis (Q78550077)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12443660%20AND%20SRC:MED&resulttype=core&format=json

15 December 2019

title

Saponins, IL12 and BCG adjuvant in the FML-vaccine formulation against murine visceral leishmaniasis (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12443660%20AND%20SRC:MED&resulttype=core&format=json

15 December 2019

main subject

visceral leishmaniasis

1 reference

Wania Renata Santos

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12443660%20AND%20SRC:MED&resulttype=core&format=json

15 December 2019

Valeria M F de Lima

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12443660%20AND%20SRC:MED&resulttype=core&format=json

15 December 2019

Edilma Paraguai de Souza

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12443660%20AND%20SRC:MED&resulttype=core&format=json

15 December 2019

Robson Ronney Bernardo

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12443660%20AND%20SRC:MED&resulttype=core&format=json

15 December 2019

Marcos Palatnik

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12443660%20AND%20SRC:MED&resulttype=core&format=json

15 December 2019

Clarisa Beatriz Palatnik de Sousa

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12443660%20AND%20SRC:MED&resulttype=core&format=json

15 December 2019

publication date

1 November 2002

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12443660%20AND%20SRC:MED&resulttype=core&format=json

15 December 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12443660%20AND%20SRC:MED&resulttype=core&format=json

15 December 2019

volume

21

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12443660%20AND%20SRC:MED&resulttype=core&format=json

15 December 2019

page(s)

30-43

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12443660%20AND%20SRC:MED&resulttype=core&format=json

15 December 2019

issue

1-2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12443660%20AND%20SRC:MED&resulttype=core&format=json

Leishmania infantum, the aetiological agent of American visceral leishmaniasis (AVL)?

15 December 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900444-9

7 January 2021

The strange case of Leishmania chagasi

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900444-9

7 January 2021

Immunotherapy versus chemotherapy in localised cutaneous leishmaniasis

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900444-9

7 January 2021

Immune response in healthy volunteers vaccinated with killed leishmanial promastigotes plus BCG. I: Skin-test reactivity, T-cell proliferation and interferon-gamma production

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900444-9

7 January 2021

Vaccination of humans against cutaneous leishmaniasis: cellular and humoral immune responses

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900444-9

7 January 2021

Controlled field trials of a vaccine against New World cutaneous leishmaniasis.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900444-9

7 January 2021

Vaccination of Swiss Albino mice against experimental visceral leishmaniasis with the FML antigen of Leishmania donovani.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900444-9

7 January 2021

Autoclaved Leishmania major vaccine for prevention of visceral leishmaniasis: a randomised, double-blind, BCG-controlled trial in Sudan.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900444-9

7 January 2021

Double targeted gene replacement for creating null mutants

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900444-9

7 January 2021

Recombinant vaccinia viruses expressing GP46/M-2 protect against Leishmania infection

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900444-9

7 January 2021

A recombinant Leishmania antigen that stimulates human peripheral blood mononuclear cells to express a Th1-type cytokine profile and to produce interleukin 12.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900444-9

7 January 2021

Vaccination with DNA encoding the immunodominant LACK parasite antigen confers protective immunity to mice infected with Leishmania major

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900444-9

7 January 2021

Genetic vaccination against leishmaniasis

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900444-9

7 January 2021

Leishmania donovani surface glycoconjugate GP36 is the major immunogen component of the Fucose-Mannose Ligand (FML)

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900444-9

7 January 2021

A new approach to the phylogeny of Leishmania: species specificity of glycoconjugate ligands for promastigote internalization into murine macrophages

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900444-9

7 January 2021

Leishmania donovani: titration of antibodies to the fucose-mannose ligand as an aid in diagnosis and prognosis of visceral leishmaniasis

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900444-9

7 January 2021

The fucose-mannose ligand-ELISA in the diagnosis and prognosis of canine visceral leishmaniasis in Brazil

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900444-9

7 January 2021

Long lasting protection against canine kala-azar using the FML-QuilA saponin vaccine in an endemic area of Brazil (S�o Gon�alo do Amarante, RN)

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900444-9

7 January 2021

Three double-blind, randomized trials evaluating the safety and tolerance of different formulations of the saponin adjuvant QS-21.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900444-9

7 January 2021

Haemolytic activities of plant saponins and adjuvants. Effect of Periandra mediterranea saponin on the humoral response to the FML antigen of Leishmania donovani

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900444-9

7 January 2021

Leishmania donovani: Surface membrane carbohydrates of promastigotes

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900444-9

7 January 2021

The role of phosphoglycans in Leishmania-sand fly interactions

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900444-9

7 January 2021

Prevalence of anti-Leishmania donovani antibody among Brazilian blood donors and multiply transfused hemodialysis patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900444-9

7 January 2021

Formulation of the purified fusion protein of respiratory syncytial virus with the saponin QS-21 induces protective immune responses in Balb/c mice that are similar to those generated by experimental infection

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900444-9

7 January 2021

Formulation of an immunogenic human cytomegalovirus vaccine: responses in mice

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900444-9

7 January 2021

Subunit vaccination of mice against new world cutaneous leishmaniasis: comparison of three proteins expressed in amastigotes and six adjuvants

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900444-9

7 January 2021

Altered immunomodulating and toxicological properties of degraded Quillaja saponaria Molina saponins.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900444-9

7 January 2021

Adjuvant and haemolytic activities of 47 saponins derived from medicinal and food plants

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900444-9

7 January 2021

Haemolytic time course differences between steroid and triterpenoid saponins

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900444-9

7 January 2021

Phase 1 trial of immunological adjuvant QS-21 with a GM2 ganglioside-keyhole limpet haemocyanin conjugate vaccine in patients with malignant melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900444-9

7 January 2021

Safety profile of phase I and II preventive HIV type 1 envelope vaccination: experience of the NIAID AIDS Vaccine Evaluation Group

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900444-9

7 January 2021

A preliminary evaluation of a recombinant circumsporozoite protein vaccine against Plasmodium falciparum malaria. RTS,S Malaria Vaccine Evaluation Group

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900444-9

7 January 2021

Randomised vaccine trial of single dose of killed Leishmania major plus BCG against anthroponotic cutaneous leishmaniasis in Bam, Iran.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900444-9

7 January 2021

A randomised, double-blind, controlled trial of a killed L. major vaccine plus BCG against zoonotic cutaneous leishmaniasis in Iran

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900444-9

7 January 2021

Ability of macrophage subsets to transfer resistance to murine leishmaniasis is dependent on IL-12 production

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900444-9

7 January 2021

Immunostimulatory oligodeoxynucleotides promote protective immunity and provide systemic therapy for leishmaniasis via IL-12- and IFN-gamma-dependent mechanisms

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900444-9

7 January 2021

Leishmania donovani p36(LACK) DNA vaccine is highly immunogenic but not protective against experimental visceral leishmaniasis

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900444-9

7 January 2021

Vaccination of dogs against Babesia canis infection using parasite antigens from in vitro culture

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900444-9

7 January 2021

The control of the antibody isotype response to recombinant human immunodeficiency virus gp120 antigen by adjuvants

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900444-9

7 January 2021

Emergency vaccination of sheep against foot-and-mouth disease: protection against disease and reduction in contact transmission

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900444-9

7 January 2021

Infecções experimentaes na Leishmaniose visceral americana

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900444-9

7 January 2021

10.1016/S0264-410X(02)00444-9

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12443660%20AND%20SRC:MED&resulttype=core&format=json

15 December 2019

1 reference